The PI3K/AKT/mTOR pathway has a critical role in the pathogenesis of HCC, and it has emerged to be an important therapeutic target for anticancer drug development, since many clinical studies have indicated that activation and deregulation of PI3K/Akt pathway play roles in various human cancers [40, 41]. The gene discussed is MTOR; the disease is hepatocellular carcinoma.